About Chaperone Technologies
Chaperone Technologies, Inc. is developing antimicrobial products, based on a novel and proprietary mechanism of action, for difficult-to-treat and drug-resistant organisms across a broad range of infectious diseases. Chaperone's proven technology has already yielded the company's first product, a potent antimicrobial which is in development for treating complicated drug resistant Urinary Tract Infections.
Missing: Chaperone Technologies's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Chaperone Technologies's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Chaperone Technologies Frequently Asked Questions (FAQ)
Where is Chaperone Technologies's headquarters?
Chaperone Technologies's headquarters is located at 1200 Liberty Ridge Drive, Wayne.
What is Chaperone Technologies's latest funding round?
Chaperone Technologies's latest funding round is Unattributed VC.
How much did Chaperone Technologies raise?
Chaperone Technologies raised a total of $100K.
Who are the investors of Chaperone Technologies?
Investors of Chaperone Technologies include Life Sciences Greenhouse of Central Pennsylvania.
Who are Chaperone Technologies's competitors?
Competitors of Chaperone Technologies include Pfenex, Aphios, Hawaii Biotech, Array Biopharma, PDS Biotechnology and 12 more.
Compare Chaperone Technologies to Competitors
Zetra Biologicals is a preclinical stage biopharmaceutical company developing vaccines against pandemic influenza and other infectious diseases.
has a broad product portfolio that modulates the immune system. Their research focuses on developing and commercializing novel vaccines and antibody-based therapies that prevent and treat infectious, autoimmune and addictive diseases, such as Staphylococcus aureus and hepatitis infections, and nicotine addiction.
SensiGen is a biotechnology company. They specialize creating tests to screen for diseases more efficiently and quickly. Their goal is to lower the overall costs of diagnosing serious diseases, usually ones where not many diagnostic tests exist.
AM-Pharma is a biopharmaceutical company that focuses on the development of recombinant Alkaline Phosphatase for clinical use.
Neugenesis Corporation is focused on generating better biotherapeutics, cost-effectively. To this end, Neugenesis has developed technology for the discovery, improvement and production of complex proteins; especially heteromeric proteins. The Company's work with the filamentous fungi Neurospora crassa has resulted in significant advances in three important areas of biotechnology: directed evolution, combinatorial biology and recombinant protein expression.
TargAnox offers therapeutics to treat diseases resulting from oxidative stress-induced protein aging
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.